Document Type : Original Article
Authors
- . Ali Kazemi‑Karyani
- . Roya Safari‑Faramani
- . Saeed Amini 1
- . Vajiheh Ramezani‑Doroh 2
- . Farzan Berenjian 3
- . Mohammad Yahyavi Dizaj 4
- . Reza Hashempour 3
- . Jafar Yahyavi Dizaj 3
1 Department of Health Management, Health School, Arak University of Medical Sciences, Arak, Iran
2 Modeling Of Noncommunicable Diseases Research Center, Hamadan University of Medical Sciences, Hamadan, Iran Department of Health Management and Economics, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran
3 Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
4 Department of Psychology, Payame Noor University, Urmia, Iran
Abstract
BACKGROUND: The prevalence of viral diseases is on the rise and has caused many problems
for public health. COVID‑19 is a new viral outbreak in the world. This study aimed to investigate the
trends of incidence and case fatality rate (CFR) of COVID‑19 in the world by April 30, 2020.
METHODS: This was a descriptive‑analytical study. We investigated the number of cases and deaths
in 35 selected countries and regions of the WHO that had at least 10,000 cases by the time of the
study. In addition, the incidence and CFR of COVID‑19 were investigated. Finally, time trends of the
number of cases, deaths, and CFR were investigated using ordinary least squares regression models.
RESULTS: The total number of confirmed cases of COVID‑19 was 3,090,184. The European region
had the highest number of COVID‑19 patients (1,434,649 [46.43%]). Ukraine with 10,406 and the
USA with 1,003,974 cases have reported the lowest and highest confirmed cases, respectively. In
addition, the European region and the African region with 157.13 and 2.50 patients per 100,000
population had the highest and the lowest incidence rate, respectively. India (2.44) and Spain (455.69)
had the lowest and the highest incidence rate per 100,000 population, respectively. In the world,
217,759 deaths have happened, of which 135,961 (62.44%) were reported in the European region.
Furthermore, the USA had the highest number of deaths (52,428) due to COVID‑19. CFR was 7.05%
in the world, which ranged from 3.74% in the African region and 9.48% in the European region. The
number of patients and deaths due to COVID‑19 had increasing trends in all countries, and the trend
of CFR just for Iran and Ukraine was negative.
CONCLUSION: The countries had different trends in the morbidity and mortality of COVID‑19.
However, regarding the increasing trend of the disease in the world, it will be more important to rely
on public prevention strategies. It is necessary to apply and continue public health policies at national
and global levels till the control of the disease.
Keywords
Features, Evaluation and Treatment Coronavirus (COVID‑19). In:
StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing;
2020 Jan‑. Available from: https://www.ncbi.nlm.nih.gov/
books/NBK554776/. [Last updated on 2020 May 18].
2. Weston S, Frieman MB. COVID‑19: Knowns, unknowns, and
questions. mSphere 2020;5(2):e00203‑20 DOI: 10.1128/mSphere.
00203‑20.
3. Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ, et al.
Epidemiology, causes, clinical manifestation and diagnosis,
prevention and control of coronavirus disease (COVID‑19) during
the early outbreak period: A scoping review. Infect Dis Poverty
2020;9:29.
4. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The
origin, transmission and clinical therapies on coronavirus disease
2019 (COVID‑19) outbreak‑an update on the status. Mil Med Res
2020;7:11.
5. Yoo JH. The fight against the 2019‑nCoV outbreak: An arduous
march has just begun. J Korean Med Sci 2019;35:e56.
6. Kamel Boulos MN, Geraghty EM. Geographical tracking and
mapping of coronavirus disease COVID‑19/severe acute
respiratory syndrome coronavirus 2 (SARS‑CoV‑2) epidemic
and associated events around the world: How 21st century GIS
technologies are supporting the global fight against outbreaks
and epidemics. Int J Health Geogr 2020;19:8.
7. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute
respiratory syndrome coronavirus 2 (SARS‑CoV‑2) and corona
virus disease‑2019 (COVID‑19): The epidemic and the challenges.
Int J Antimicrob Agents 2020;55:105924.
8. Schwartz DA. An analysis of 38 pregnant women with COVID‑19,
their newborn infants, and maternal‑fetal transmission of
SARS‑CoV‑2: Maternal coronavirus infections and pregnancy
outcomes. Arch Pathol Lab Med 2020; DOI: 10.5858/arpa.
2020‑0901‑SA
9. Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. A rapid
advice guideline for the diagnosis and treatment of 2019 novel
coronavirus (2019‑nCoV) infected pneumonia (standard version).
Mil Med Res 2020;7:4.
10. Shanmugaraj B, Siriwattananon K, Wangkanont K,
Phoolcharoen W. Perspectives on monoclonal antibody
therapy as potential therapeutic intervention for Coronavirus
disease‑19 (COVID‑19). Asian Pac J Allergy Immunol 2020;38:10‑8.
11. Zhang Y. Analysis of Epidemiological characteristics of new
coronavirus pneumonia. Chin J Epidemiol 2020;41:1‑7.
12. Riou J,Althaus CL. Pattern of early human‑to‑human transmission
of Wuhan 2019 novel coronavirus (2019‑nCoV), December 2019
to January 2020. Euro Surveill 2020;25:2000058.
13. Liu Y, Gayle AA, Wilder‑Smith A, Rocklöv J. The reproductive
number of COVID‑19 is higher compared to SARS coronavirus.
J Travel Med 2020;27:taaa021.
14. Fan VY,Jamison DT, Summers LH. The inclusive cost of pandemic
influenza risk. Natl Bureau Economic Res 2016;22137:0898‑2937.
15. Programme UN. A socio‑Economic Impact Assessment of the
Zika virus in Latin America and the Caribbean: With a Focus on
Brazil, Colombia and Suriname. New York, NY: United Nations
Development Programme; 2017.
16. Lee BY, Alfaro‑Murillo JA, Parpia AS, Asti L, Wedlock PT,
Hotez PJ, et al. The potential economic burden of Zika in the
continental United States. PLoS Negl Trop Dis 2017;11:e0005531.
17. Huber C, Finelli L, Stevens W. The economic and social
burden of the 2014 ebola outbreak in West Africa. J Infect Dis
2018;218:S698‑704.
18. Qiu W, Chu C, Mao A, Wu J. The impacts on health, society,
and economy of SARS and H7N9 outbreaks in China: A case
comparison study. J Environ Public Health 2018;2018:1-7.
19. Colak S, Kandis H, Afacan MA, Erdogan MO, Gunes H, Kaya E,
et al. Assessment of patients who presented to the emergency
department with mushroom poisoning. Hum Exp Toxicol
2015;34:725‑31.
20. OECD. COVID‑19: SME Policy Responses; 16 March, 2020.
21. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J,
Bondi‑Zoccai G, et al. Cardiovascular considerations for patients,
health care workers, and health systems during the coronavirus
disease 2019 (COVID‑19) pandemic. J Am Coll Cardiol
2020;75:2352-71.
22. Moradi G, Piroozi B, Mohamadi‑Bolbanabad A, Safari H,
Shokri A, Rahimi R. Can judgments according to case fatality rate
be correct all the time during epidemics? Estimated cases based
on CFR in different scenarios and some lessons from early case
fatality rate of coronavirus disease 2019 in Iran. Med J Islamic
Republic Iran (MJIRI) 2020;34:178‑82.
23. WHO. Coronavirus Disease 2019 (COVID‑19) Situation
Report – 101; 30 March, 2020.
24. Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD.
How will country‑based mitigation measures influence the course
of the COVID‑19 epidemic? Lancet 2020;395:931‑4.
25. Fisher D, Heymann DJ. Q&A: The novel coronavirus outbreak
causing COVID‑19. BMC Medicine 2020;18:1‑3.
26. Li Q,Guan X,Wu P,Wang X,Zhou L,Tong Y,etal. Early transmission
dynamics in Wuhan, China, of novel coronavirus‑infected
pneumonia. N Engl J Med 2020;382:1199‑207.
27. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y,et al. Clinical features
of patients infected with 2019 novel coronavirus in Wuhan, China.
Lancet 2020;395:497‑506.
28. Battegay M, Kuehl R, Tschudin‑Sutter S, Hirsch HH, Widmer AF,
Neher RA. 2019‑novel coronavirus (2019‑nCoV): Estimating the
case fatality rate‑a word of caution. Swiss Med Weekly 2020;150:
w20203.
29. National Health Commission of the People’s Republic of
China. Diagnosis and Treatment Guideline on Pneumonia
Infection with 2019 Novel Coronavirus (5th Trial ed). Available
from: http://www.nhc.gov.cn/xcs/zhengcwj/202002/
d4b895337e19445f8d728fcaf1e3e13a.shtml. [Last accessed on 2020
Feb 18].
30. Zhang J, Litvinova M, Wang W, Wang Y, Deng X, Chen X, et al.
Evolving epidemiology of novel coronavirus diseases 2019 and possible interruption of local transmission outside Hubei Province
in China: A descriptive and modeling study. medRxiv 2020;
doi: 10.1101/2020.02.21.20026328.
31. Wong JEL, Leo YS, Tan CC. COVID‑19 in Singapore‑current
experience: Critical global issues thatrequire attention and action.
JAMA 2020;323(13):1243‑4.
32. Porcheddu R, Serra C, Kelvin D, Kelvin N, Rubino S. Similarity
in case fatality rates (CFR) of COVID‑19/SARS‑COV‑2 in Italy
and China. J Infect Dev Ctries 2020;14:125‑8.
33. Drake JM, Chew SK, Ma S. Societal learning in epidemics:
Intervention effectiveness during the 2003 SARS outbreak in
Singapore. PLoS One 2006;1:e20.
34. Yuan J, Li M, Lv G, Lu ZK. Monitoring transmissibility and
mortality of COVID‑19 in Europe. Int J Infect Dis 2020;95:311‑5.
35. India P. Future of India‑The Winning Leap; 2014.
36. Remuzzi A, Remuzzi GJ. COVID‑19 and Italy: What next? Health
policy 2020;395:1225‑8.
Onder G, Rezza G, Brusaferro S. Case‑fatality rate and
characteristics of patients dying in relation to COVID‑19 in Italy.
JAMA 2020;323:1749‑862.
37. Klompas M. Coronavirus Disease 2019 (COVID‑19): Protecting
Hospitals From the Invisible. Ann Intern Med 2020;172:619‑20.
38. Parodi SM, Liu VX. From containment to mitigation of COVID‑19
in the US. JAMA 2020;323:1441‑2.
39. Pillaiyar T, Meenakshisundaram S, Manickam MJ. Recent
discovery and development of inhibitors targeting coronaviruses.
Drug Discov Today 2020;25:668-88.
40. CDC U. Novel coronavirus - Information for Healthcare
Professionals; 2020. Available from: https://www.cdc.gov/
coronavirus/2019‑nCoV/hcp/index.html. [Last accessed on 2020
Mar 29].
41. Lu H. Drug treatment options for the 2019‑new coronavirus
(2019‑nCoV). Biosci Trends 2020;14:69‑71.
42. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ,et al.
Comparative therapeutic efficacy ofremdesivir and combination
lopinavir, ritonavir, and interferon beta against MERS‑CoV. Nat
Commun 2020;11:222.
43. Goudarzi R, Tasavon Gholamhoseini M, Amini S, Nakhaei M,
Dehnavieh R. Estimating the cost of vaccination in southeastern
Iran. Hum Vaccin Immunother 2020;1‑7. https://doi.org/10.10
80/21645515.2020.1725357.
44. World Health Organization. Coronavirus Disease 2019
(COVID‑19) Situation Report‑44. Available from: https://
www.who.int/docs/default‑source/coronaviruse/situationreports/20200304‑sitrep‑44‑covid‑19.pdf?sfvrsn=783b4c9d_2.
[Last accessed on 2020 Mar 04; Last accessed on 2020 Mar 05].
)